Table 1.
Genotypes and alleles in the half-marathon runners with respect to finish time.
| ACE (HWE, χ2 = 1.8, p = 0.180) | |||||
|---|---|---|---|---|---|
| Group (HWE) | II ( n = 50) | ID (n = 81) | DD (n = 49) | I | D |
| <100 (χ2 = 0.38, p = 0.538) | |||||
| 24 (31.6%) | 35 (46.1%) | 17 (22.4%) | 83 (54.6%) | 69 (45.4%) | |
| (n = 76) | |||||
| >100 (χ2 = 1.31, p = 0.252) | 26 (25.0%) | 46 (44.2%) | 32 (30.8%) | 98 (47.1%) | 110 (52.9%) |
| (n = 104) | p = 0.396 | p =0.160 | |||
| BDKRB2 (HWE, χ2 = 0.13, p = 0.718) | |||||
| -/- (n = 32) | +/- (n = 85) | +/+ (n = 63) | - | + | |
| <100 (χ2 = 0.32, p = 0.572) | 14 (18.4%) | 40 (52.6%) | 22 (29.0%) | 68 (44.7%) | 84 (55.3%) |
| >100 (χ2 = 0.84, p = 0.359) | 18 (17.3%) | 45 (43.3%) | 41 (39.4%) | 81 (38.9%) | (61.1127%) |
| p = 0.329 | p = 0.270 | ||||
| NOS3 (HWE, χ2 = 0.01, p = 0.920) | |||||
| Glu/Glu (n = 88) | Glu/Asp (n = 76) | Asp/Asp (n = 16) | Glu | Asp | |
| <100 (χ2 = 0.32, p = 0.572) | 38 (50.0%) | 30 (39.5%) | 8 (10.5%) | (69.7106 %) | 46 (30.3%) |
| >100 (χ2 = 0.34, p = 0.560) | 50 (48.1%) | 46 (44.2%) | 8 (7.7%) | (70.2146 %) | 62 (29.8%) |
| p = 0.717 | p = 0.926 | ||||
| AMPD1 (HWE, χ2 = 3.49, p = 0.062) | |||||
| CC (n = 136) | CT (n = 44) | TT (n = 0) | C | T | |
| <100 (χ2 = 4.99, p = 0.025) | 45 (59.2%) | 31 (40.8%) | 0 (0) | (79.6121 %) | 31 (20.4%) |
| >100 (χ2 = 2.58, p = 0.108) | 91 (87.5%) | 13 (12.5%) | 0 (0) | (93.8195 %) | 13 (6.3%) |
| p = 0.00001 | p = 0.00005 | ||||
| UCP2 (HWE, χ2 = 1.85, p = 0.174) | |||||
| CC (n = 58) | CT (n = 96) | TT (n = 26) | C | T | |
| <100 (χ2 = 13.54, p=0.0002) = | 12 (15.8%) | 54 (71.1%) | 10 (13.2%) | 78 (51.3%) | 74 (48.7%) |
| >100 (χ2 = 1.47, p = 0.225) | 46 (44.2%) | 42 (40.4%) | 16 (15.4%) | (64.4134 %) | 74 (35.6%) |
| p = 0.00008 | p = 0.0125 | ||||